YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors

• Published in: Clinical cancer research 2006-03, Vol.12 (5), p.1630-1638
• Main Authors: Amino, Nobuaki, Ideyama, Yukitaka, Yamano, Mayumi, Kuromitsu, Sadao, Tajinda, Katsuinori, Samizu, Kiyohiro, Hisamichi, Hiroyuki, Matsuhisa, Akira, Shirasuna, Kenna, Kudoh, Masafumi, Shibasaki, Masayuki
• Format: Article
• Language: English
• Subjects: Administration, Oral; angiogenesis; Angiogenesis Inhibitors - therapeutic use; Animals; Antineoplastic Agents, Phytogenic - therapeutic use; antitumor activity; Biological Availability; Cell Proliferation - drug effects; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; endothelial cells; Female; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - pathology; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - prevention & control; Paclitaxel - therapeutic use; Phosphorylation - drug effects; Piperazines - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Quinazolines - therapeutic use; Thiazoles - therapeutic use; Tumor Cells, Cultured; vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular Endothelial Growth Factor A - metabolism; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; Vascular Endothelial Growth Factor Receptor-2 - metabolism; Xenograft Model Antitumor Assays; YM-359445
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-05-2028

Purpose: The vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase has been implicated in the pathologic angiogenesis associated with tumor growth. YM-359445 was a (3 Z )-3-quinolin-2(1 H )-ylidene-1,3-dihydro-2 H -indol-2-one derivative found while screening based on the inhibition of VEGFR2 tyrosine kinase. The aim of this study was to analyze the efficacy of this compound both in vitro and in vivo . Experimental Design: We tested the effects of YM-359445 on VEGFR2 tyrosine kinase activity, cell proliferation, and angiogenesis. The antitumor activity of YM-359445 was also tested in nude mice bearing various established tumors and compared with other VEGFR2 tyrosine kinase inhibitors (ZD6474, CP-547632, CGP79787, SU11248, and AZD2171), a cytotoxic agent (paclitaxel), and an epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib). Results: The IC 50 of YM-359445 for VEGFR2 tyrosine kinase was 0.0085 μmol/L. In human vascular endothelial cells, the compound inhibited VEGF-dependent proliferation, VEGFR2 autophosphorylation, and sprout formation at concentrations of 0.001 to 0.003 μmol/L. These concentrations had no direct cytotoxic effect on cancer cells. In mice bearing various established tumors, including paclitaxel-resistant tumors, once daily oral administration of YM-359445 at doses of 0.5 to 4 mg/kg not only inhibited tumor growth but also reduced its vasculature. YM-359445 had greater antitumor activity than other VEGFR2 tyrosine kinase inhibitors. Moreover, in human lung cancer A549 xenografts, YM-359445 markedly regressed the tumors (73%) at a dose of 4 mg/kg, whereas gefitinib caused no regression even at 100 mg/kg. Conclusion: Our results show that YM-359445 is more potent than orally bioavailable VEGFR2 tyrosine kinase inhibitors, which leads to great expectations for clinical applicability.